Novan Conducts Guidance Meeting with FDA on SB204 Development Program

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has concluded a guidance meeting with the U.S. Food and Drug Administration (FDA) regarding SB204 for the treatment of acne vulgaris. The FDA advised that an additional pivotal trial should be conducted. Given the need for the additional clinical study, the agency treated this meeting as a guidance meeting rather than a pre-NDA meeting. The Company anticipates receiving written minutes of the meeting within the next 30 days.